Global pharmaceutical company Daiichi Sankyo has received approval from the US Food and Drug Administration (FDA) to package product at its first US-based packaging facility in Bethlehem, Pennsylvania.
Daiichi Sankyo said the approval allows the company to expand its global supply chain capability, while helping to ensure the supply of medicine to US physicians and their patients.
Daiichi Sankyo operations vice president Jeff Lane said the company incorporated new technology in the design and development of the Bethlehem facility, from facility and process design to quality control and personnel flow.
"The commissioning of this facility is a major milestone for our U.S. organization and augments our ability to manufacture and distribute quality medicines," Lane added.
At present, some of the company’s portfolio of marketed products for cardiovascular and metabolic therapies including treatments for hypertension and heart disease, diabetes and hyperlipidemia are packed at the 140,000ft² facility.
By expanding its business operations, the company is helping to minimize risks associated with product supply and is able to gain control over the products’ life cycle, from research and development through packaging and distribution.